Developer of revolutionizing medical device products for male infertility, individualizing In Vitro Fertilization (IVF) diagnostics and treatment creating a new standard for faster and safer IVF treatments. Spermosens is listed on Spotlight Stock Market since 5th of May 2021.
WHO is estimating that globally 48 million couples and 186 million individuals can be affected by infertility. For couples, sub male fertility is the explanation to the problem in at least 50 % of the cases. Spermosens is developing a revolutionizing technology for male fertility diagnostics and fertility treatment.
With Spermosens first product, JUNO- Checked, it will – for the first time – be possible to determine a sperms ability to fertilize the egg cell. This in turn enables the IVF clinic to choose the appropriate fertilization treatment. Today, around 85 percent of IVF treatments fail. Being able to determine the sperm’s ability to fertilize the egg cell is expected to cause to a reduction in the number of IVF-treatments. This leads to:
- Reduced waiting period for childless couples
- Less negative phycological effects
- Reduced cost for the couples in treatment
- Reduced need for hormonal treatments of the female
- Increased capacity of each IVF clinic
- Improved financial outlook for IVF clinics
”We estimate the global sales potential to be around five billion SEK per year, assuming that all of the 5.000 clinics, which we have identified as potential clients, make use of JUNO-Checked for all of their IVF treatments. We won’t be able to reach the entirety of the global market at once, but with our unique product offering and competitive edge, I predict that we will be able to capture a very high market share”.
John Lempert, CEO